Abstract B38: Pilot study of combination PSMA peptide and TARP peptide vaccine with poly-IC:LC adjuvant in HLA-A2 positive patients with elevated PSA after initial definitive treatment of prostate cancer | Citedby Results | Cancer Immunology Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract B38: Pilot study of combination PSMA peptide and TARP peptide vaccine with poly-IC:LC adjuvant in HLA-A2 positive patients with elevated PSA after initial definitive treatment of prostate cancer

Cancer Immunol Res (2015) 3 (10_Supplement): B38.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?

Anna Patrikidou
Thomas Zilli
Giulia Baciarello
Safae Terisse
Zineb Hamilou
Karim Fizazi

Therapeutic Advances in Medical Oncology (2021) 13: 175883592110518.

More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond

Anniina Hyväkkä
Verneri Virtanen
Jukka Kemppainen
Tove J. Grönroos
Heikki Minn
Maria Sundvall

Cancers (2021) 13 (9): 2244.